Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency
The DOI matches its Crossref record.
Abstract
The physiological significance of the hyperglucagonemia that occurs in patients with many catabolic conditions is unclear. The effect of hyperglucagonemia on resting metabolic rate (RMR) was studied in six normal subjects. Infusion of somatostatin (SRIH; 500 micrograms/h for 210 min) resulted in a 5-fold decrease in plasma C-peptide and a 2-fold decrease in plasma insulin and glucagon concentrations, but did not change RMR significantly. When glucagon (0.2 micrograms/kg X h), was infused with SRIH (500 micrograms/h for 210 min), the decreases in plasma C-peptide and insulin were similar to that during the infusion of SRIH alone, but plasma glucagon increased from 160 +/- 24 (+/- SEM) to 560 +/- 80 pg/mL (P less than 0.001). There was a significant increase in RMR during the entire period (210 min) of glucagon infusion (P less than 0.01). During the last hour of the glucagon plus SRIH infusion, the RMR was 1.38 +/- 0.10 Cal/min, which was 15% higher than the preinfusion RMR (1.19 +/- 0.10 Cal/min; P less than 0.01) and 14% higher than the RMR during the same period when SRIH alone was infused (1.21 +/- 0.11 Cal/min; P less than 0.01). When SRIH and glucagon were infused, protein oxidation (calculated from urinary nitrogen loss) was 52 +/- 5 mg/min, 29% higher than when SRIH alone was infused (40 +/- 5 mg/min; P less than 0.05). These results indicate that hyperglucagonemia during insulin deficiency results in an increase in energy expenditure, which may contribute to the catabolic state in many conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides, small-scale studies support the ability of glucagon receptor activation to increase metabolic rate in both fed and fasted conditions, making the glucagoneglucagon receptor axis an attractive therapeutic approach to combine with anti-obesity medications that work by reducing caloric intake (Nair, 1987;Tan et al, 2013;Salem et al, 2016;Stahel et al, 2019).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Nair, 1987
In the citing paper
“Moreover, glucagon, whose effects on blood glucose counteract insulin's, has a thermogenic effect (50).”
From Altered mitochondrial function in insulin-deficient and insulin-resistant states (2018) · cites this paper as [50]
Citations
Cites
Still being checked.
Cited by
Items 101–141 of 141
Vogiatzi, M. G., Nair, K. S., Beckett, P. R., & Copeland, K. C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4417 · Cited by 13
Self-citationEpinephrine's effect on metabolic rate is independent of changes in plasma insulin or glucagon
Staten, M. A., Matthews, D. E., Cryer, P. E., & Bier, D. M. (1989) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1989.257.2.e185 · Cited by 12
New Developments in Glucagon Treatment for Hypoglycemia
Hayward, L., & Wilson, L. M. (2022) · Drugs · doi:10.1007/s40265-022-01754-8 · Cited by 11
Chronic lipoic acid treatment worsens energy imbalances in streptozotocin-induced diabetic rats
Luz, J., Zemdegs, J. C. S., & Amaral, L. S. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.08.005 · Cited by 11
Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Ruocco, C., Malavazos, A. E., Ragni, M., Carruba, M. O., Valerio, A., Iacobellis, G., & Nisoli, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106892 · Cited by 11
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
Lasher, A. T., & Sun, L. Y. (2023) · Aging Cell · doi:10.1111/acel.13985 · Cited by 9
Hormone and Cytokine Regulation of Injury Metabolism
Lowry, S. F. (1993) · Springer eBooks · doi:10.1007/978-3-642-84904-6_1 · Cited by 11
Guo, H., Sui, C., Ge, S., Cai, J. Q., Lin, D., Guo, Y., Wang, N., Zhou, Y., Ying, R., Zha, K., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3550 · Cited by 8
Regulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
Kayed, A., Melander, S. A., Khan, S., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001440 · Cited by 7
Nepocatych, S., Melson, C. E., Madzima, T. A., & Balilionis, G. (2019) · Appetite · doi:10.1016/j.appet.2019.104322 · Cited by 7
Energy balance of pregnant diabetic rats
Yamada, R., Griggio, M. A., & Luz, J. (2002) · British Journal Of Nutrition · doi:10.1079/bjnbjn2001520 · Cited by 5
Nakagawa, M., Shinozawa, Y., Ando, N., Aikawa, N., & Kitajima, M. (1994) · Surgery Today · doi:10.1007/bf01636773 · Cited by 5
Energy expenditure, body composition, and biochemical indicators in healthy community women
Nies, M. A., Chen, K. Y., & Wal, J. S. V. (2004) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637480410001734120 · Cited by 5
Gastaldelli, A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.029 · Cited by 4
Nair, K. S. (2025) · Diabetic Medicine · doi:10.1111/dme.70086 · Cited by 3
Self-citationFranklin, Z. J., Lafferty, R. A., Flatt, P. R., McShane, L. M., O'Harte, F. P. M., & Irwin, N. (2022) · Biochimie · doi:10.1016/j.biochi.2022.04.005 · Cited by 4
Cho, Y. H., & Lee, S. Y. (2013) · The Korean Journal of Obesity · doi:10.7570/kjo.2013.22.4.197 · Cited by 2
Assessment of estimated and measured resting metabolic rates in type 1 and type 2 diabetes mellitus
Dayan, A., Ergen, N., & Bulgurlu, S. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28248 · Cited by 2
Glucagon and the metabolic syndrome
Welch, A., & Vella, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00011-6 · Cited by 2
Elmendorf, A. J., Furber, E. C., Lorentz, B., Mahler, C. A., Droz, B. A., Cosgrove, R., Poret, J. M., Knerr, P. J., Samms, R. J., & Flak, J. N. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102328 · Cited by 1
GLP-1 Is Not Enough: Can Glucagon Fill the Energy Expenditure Gap?
Beji, S., & Caron, A. (2026) · Neuroendocrinology · doi:10.1159/000550812 · Cited by 1
A Study on Plant Based Dietary Patterns and Cancer Risk
Purada, N., Matada, K., Philippe, M. M., & Koneri, R. (2013) · Cited by 1
Glucagon in Islet and Metabolic Regulation
Sandoval, D. A., Tong, J., & Alessio, D. D. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch7 · Cited by 1
Dietary proteins : their effect on insulin and glucagons in relation to body weight management
Claessens, M. (2008) · Research Publications (Maastricht University) · doi:10.26481/dis.20080116mc · Cited by 1
Type I Diabetes and the Role of Inflammatory-Related Cellular Signaling
Jesse, L. M., Andrew, K. M., Myung, C., & Stef, K. (2011) · InTech eBooks · doi:10.5772/24581
The role of gut hormones on food intake and carbohydrate tolerance
Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846
Loyd, C. (2014) · OhioLink ETD Center (Ohio Library and Information Network)
Glucose Homeostasis and the Burnt-Out Diabetes Phenomenon in Patients with Kidney Disease
Abe, M., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_3
Os leucotrienos no diabetes tipo 1
Ramalho, T. R. D. O. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2019.tde-18042019-141413
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Nicol, A., Ahmed, M., Fischer, C., Garces, J. G., Magnus, S., Maung, N., Molisani, N., Petrov, S., & Palu, R. A. S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302565
Multi‐target Peptides for the Treatment of Metabolic Diseases
Bossart, M., & Heßler, G. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch20
Uncoupling Insulin Sensitivity From Longevity: A Sex‐Dependent Effect of Hepatic Glucagon Signaling
Lasher, A. T., Heckman, B., Sarker, P., Liu, K., & Sun, L. Y. (2026) · Aging Cell · doi:10.1111/acel.70349
Glucagon Synthesis, Secretion, and Mechanisms of Action
Mohan, S., & Vella, A. V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00005-6
Metadata
- Authors
- NAIR, K. S.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- NAIR, K. SREEKUMARAN
- ORCID
- NAIR, K. SREEKUMARAN
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1987-05
- Volume
- 64
- Issue
- 5
- Pages
- 896-901
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2085655607
- Cited by
- 141
- References
- 0
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 10 · 2022: 12 · 2021: 6 · 2020: 5 · 2019: 15 · 2018: 11 · 2017: 3 · 2016: 6 · 2015: 2 · 2014: 3 · 2013: 10 · 2012: 3
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AM-20494)
- National Center for Research Resources (RR-00044, RR05403)
- NIH Clinical Center
- Rocky Mountain Research Station
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- hyperglucagonemia, resting metabolic rate, insulin deficiency, somatostatin, glucagon infusion, C-peptide, protein oxidation, energy expenditure, catabolic state, urinary nitrogen loss
- MeSH terms
- Adult, Basal Metabolism, Blood Glucose, C-Peptide, Energy Metabolism, Female, Glucagon, Humans, Insulin, Kinetics, Male, Oxygen Consumption, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.